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Abstract Leukocyte adhesion deficiency type II (LAD II) is a
rare genetic disease characterized by severe immunodeficiency
which is related to defective expression in leukocytes of sialyl-
Lewis X (SLeX), a fucosylated ligand for endothelial selectins.
The molecular basis of LAD II is still unknown, but has been
tentatively localized in the de novo pathway of GDP-L-fucose
biosynthesis from GDP-D-mannose. Here, we demonstrate that
in cell lysates from a LAD II patient, GDP-D-mannose-4,6-
dehydratase (GMD), the first of the two enzymes of the pathway
has a defective activity compared to control subjects. GMD in
cell lysates from both parents showed intermediate activity levels.
Cloning of GMD from patient and control lymphocytes ruled out
any mutation affecting the amino acid GMD sequence and the
purified recombinant proteins from both controls and the patient
showed identical specific activities. Since the levels of immuno-
reactive GMD in cell lysates were comparable in the patient and
in controls, the biochemical deficiency of intracellular GMD
activity in LAD II seems to be due to mutation(s) affecting some
still unidentified GMD-regulating protein.
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1. Introduction
Leukocyte adhesion de¢ciency type II (LAD II) is an auto-
somal recessive congenital disease, characterized by immuno-
de¢ciency and severe mental and growth retardation [1,2].
These patients also display a Bombay phenotype and lack
of sialyl-Lewis X (SLeX) antigen on the leukocyte surface
[1]. SLeX is a fucose-containing glycoconjugate ligand for
the selectins expressed on endothelial cells and on lympho-
cytes [3^7]. The interaction between SLeX and selectins is
the ¢rst of a series of events mediating leukocyte rolling and
the subsequent extravasation to start the in£ammatory re-
sponse [7]. Granulocytes from LAD II patients have been
demonstrated to fail both to interact with cytokine-activated
endothelial cells and to bind to recombinant E-selectin in vitro
[8,9]. Moreover, in vivo experiments in the patients revealed
impaired chemotaxis, reduced half-life and increased turnover
rate of neutrophils [10]. These defects in granulocyte functions
have been related to the lack of SLeX expression on leuko-
cytes, which prevents interaction with selectins, thus inhibiting
their tissue extravasation and causing the immunode¢ciency.
The widespread lack of L-fucose on several di¡erent glyco-
conjugates seems to exclude any impairment of fucosyltrans-
ferase activities. Rather, it has been proposed that the adhe-
sion de¢ciency is due to a general defect in L-fucose
metabolism [1,2], in particular in the intracellular production
of GDP-L-fucose, the substrate of fucosyltransferase activities.
However, the molecular basis of the LAD II syndrome is still
unknown. In normal cells, GDP-L-fucose is produced either
by a de novo pathway starting from GDP-D-mannose or from
a quantitatively minor pathway of L-fucose salvage (for a re-
view see [11]). Cytosolic GDP-L-fucose is then transported
across Golgi membranes by a speci¢c translocation system
[12] and donates the L-fucose moiety to several glycoconjugate
acceptors via di¡erent fucosyltransferases [6,13]. The major de
novo biosynthetic pathway, initially described by Ginsburg in
the 1960s [14,15], involves ¢rst a dehydration of GDP-D-man-
nose to GDP-4-keto-6-deoxy-D-mannose, catalyzed by a
GDP-D-mannose 4,6 dehydratase (GMD), and then a double
epimerase and NADPH-dependent reductase reaction, cata-
lyzed by a single protein. GMD has been identi¢ed and char-
acterized in several organisms, from Escherichia coli [16] to
human cells [17], and it proves to be very well conserved
during evolution, with more than 60% amino acid identity
between the bacterial and human enzymes. The double epi-
merase/reductase activity of the second enzyme has been ini-
tially proposed by Chang et al. [18] for the protein puri¢ed
form porcine thyroid. It was then con¢rmed with the protein
puri¢ed in our laboratory from human erythrocytes [19],
which has been identi¢ed with the human FX protein
[20,21], and also with the recombinant E. coli protein [22].
Cloning of both human enzyme proteins involved in the de
novo pathway, i.e. GMD and FX, allowed us to address the
site of LAD II de¢ciency at the biochemical level. During the
present study, human GMD was cloned from a HL-60 pro-
myelocytic cell line and its derived amino acid sequence
turned out to be identical to that independently obtained in
our laboratory [17]. The results reported in this paper un-
equivocally identify the reaction catalyzed by GMD as the
a¡ected step in LAD II cells. Interestingly, no mutation was
found in the coding region of patient GMD cDNA and no
quantitative alterations of the protein seem to be present.
These data suggest that the molecular basis of this genetic
disorder, resulting in a defective biosynthesis of cytosolic
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GDP-L-fucose, is at the level of some still unidenti¢ed factors
regulating intracellular GMD activity.
2. Materials and methods
2.1. Cell isolation and culture
Peripheral lymphocytes from the LAD II patient, from his parents
and from healthy subjects were puri¢ed from total heparinized venous
blood using the Ficoll-Hypaque procedure (Pharmacia Biotech, Upp-
sala, Sweden). Informed consent for the use of samples was obtained
from the patient’s parents and from all other subjects involved in this
study. After puri¢cation, lymphocytes were stimulated using 0.5%
PHA-M (Sigma Chemicals, St. Louis, MO, USA) and 100 U/ml hu-
man recombinant IL-2 (Genzyme, Cambridge, MA, USA) in RPMI
1640 medium containing 10% FCS and 5 mM glutamine (HyClone,
Logan, UT, USA). After 3 days of stimulation, PHA-M was removed
and cells were cultured in RPMI medium supplemented with 100 U/
ml IL-2. Alternatively, B-lymphocytes were transformed with Epstein-
Barr virus (EBV) following published protocols [23]. Transformed
cells were then maintained in RPMI 1640 medium. All cultures
were routinely screened for mycoplasma contamination.
2.2. Preparation of cell lysates and determination of enzymatic
activities
IL-2 stimulated lymphoblasts and EBV-transformed cells were har-
vested during exponential growth and washed twice with ice-cold PBS.
Cell pellets were resuspended at 100U106/ml in 100 mM sodium
phosphate bu¡er, pH 8.0, containing 0.1 mM PMSF, 40 WM AEBSF,
0.1 mM leupeptin and 50 WM pepstatin. Cells were lysed in ice using a
Dounce homogenizer with 30 strokes and were then centrifuged at
10 000Ug for 20 min a 4‡C. The supernatants were centrifuged again
at 100 000Ug for 60 min at 4‡C. All fractions obtained were used to
assay GMD activity. Protein concentration was determined according
to Bradford [24].
The activity of both individual enzymes involved in the conversion
of GDP-D-mannose to GDP-L-fucose, i.e. GMD and FX, and the
overall activity of the complete pathway were assayed as previously
described [16,19]. The activity of GMD on the cytosolic fraction was
determined in the absence of NADPH, thus preventing FX activity
and the production of GDP-L-fucose. Conversely, FX activity was
analyzed using as substrate the intermediate compound GDP-4-
keto-6-deoxy-D-mannose, which was produced using the bacterial re-
combinant GMD [16].
SDS-PAGE and Western blot analyses on the subcellular fractions
were performed as described [25,26], using a rabbit polyclonal anti-
bacterial GMD antibody, which was observed to recognize also the
human enzyme. Detection was performed with a second peroxidase-
labeled anti-rabbit IgG antibody using the ECL system (Amersham
Life Sciences, Milan, Italy), following the supplier’s instructions.
2.3. Puri¢cation and sequencing of mRNA
Patient and control RNAs were puri¢ed from both normal and
EBV-transformed lymphocytes using Trizol reagent (Life Technolo-
gies Italia, Milan, Italy). Total RNA was retrotranscribed using
MuMV-RT (Promega, Madison, WI, USA) as described [27], using
either oligo dT or gene-speci¢c primers designed on human GMD
sequence (GenBank accession number AF042377), which were ob-
tained by TibMolBiol (Genoa, Italy). PCR ampli¢cation of cDNA
with GMD gene-speci¢c primers was performed in the following con-
ditions: 1UThermo bu¡er (Promega), 1.5 mM MgCl2, 200 WM dNTP
(Pharmacia), 40 WM primers and 2.5 U Taq polymerase (Promega).
The results of ampli¢cation were analyzed by agarose gel electropho-
resis and ethidium bromide staining. Bands corresponding to the ex-
pected size were cut from the agarose gel and the ampli¢cation prod-
ucts were then puri¢ed using the Nucleospin Extract kit (Macherey-
Nagel, Duºren, Germany). After puri¢cation, PCR products were li-
gated in pMOSBlue vectors, using the pMOSBlue Blunt End cloning
kit (Amersham). Plasmids containing the correct inserts were puri¢ed
using High Pure Plasmid Isolation (Boehringer Mannheim, Milan,
Italy) and sequenced, either manually with Sequenase 2.0 (Amersham)
or using the Applied Biosystem 373A automatic sequencer.
2.4. Expression of the recombinant proteins
GMD cloned from normal and LAD II patient were expressed in
E. coli as fusion proteins with GST, using pGEX-6P1 vector (Phar-
macia). The coding region of GMD was ampli¢ed using two speci¢c
primers containing BamHI (forward) and EcoRI (reverse) restriction
sites. The ¢rst methionine, corresponding to nucleotide 76 of the
published sequence [17], was considered the starting residue. The am-
pli¢ed product was cut with the appropriate restriction enzymes, li-
gated in pGEX-6P1 vector and the ligation product was used to trans-
form competent K803 cells. DNA sequence was performed on
plasmids puri¢ed from clones positive to PCR screening. Expression
and a⁄nity puri¢cation with GSH-Sepharose (Pharmacia) of the re-
combinant proteins were performed as described [16], with slight mod-
i¢cations. Brie£y, bacterial culture was induced at an optical density
of 0.6 at 660 nm, using 0.2 mM IPTG and incubated for 4 h at 25‡C.
Cleavage of the native GMD from the matrix(GSH-Sepharose)-bound
fusion protein was achieved using Prescission Protease (Pharmacia),
upon incubating at 4‡C for 16 h. Enzymatic activities of the control
and patient GMD were assayed as previously reported for the bacte-
rial recombinant GMD [16].
Recombinant human FX protein was produced as fusion protein
with GST, using pGEX-4T2 vector (Pharmacia). The coding region of
placental FX cDNA (GenBank accession number U58766) was am-
pli¢ed by PCR, using gene-speci¢c primers containing BglII (forward)
and EcoRI (reverse) cleavage sites. The digested product was ligated
to BamHII and EcoRI cleaved sites of pGEX-4T2 and used for trans-
formation of competent K803 cells. Conditions of expression and
puri¢cation were as described [16]. The native protein was obtained
after incubation with thrombin protease (Pharmacia) for 16 h at 25‡C.
3. Results
GMD activity was ¢rst comparatively assayed in lysates of
PHA plus IL-2-stimulated lymphoblasts from the LAD II
patient and from a normal healthy subject. As shown in
Fig. 1, GMD activity was remarkably lower in the LAD II
patient than in the control subject, who was recruited from
the same geographical area of the patient and whose GMD
activity was comparable to that observed in other healthy
subjects examined in our laboratory (not shown). Another
consistent di¡erence between the two samples was the time-
dependent trend of patient GMD to regain activity as com-
pared to the control which showed conversely linear patterns
of enzymatic activity during incubation. This peculiar devia-
tion from linearity was also observed in lysates of EBV-trans-
formed lymphocytes from the LAD II patient (Fig. 2A). In
these immortalized cells, de¢ciency of GMD activity as com-
pared to the control was less pronounced than in the IL-2
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Fig. 1. GDP-D-mannose conversion to the product GDP-4-keto-6-
deoxy-D-mannose by GMD in control and LAD II patient cytosolic
fractions of PHA+IL-2-stimulated lymphoblasts. Incubations were
performed for the times indicated at 37‡C with 50 WM GDP-D-[14C-
U]mannose, using 1 mg/ml of cytosolic protein. Conditions of incu-
bation and determination of the product GDP-4-keto-6-deoxy-D-
mannose by HPLC analysis were as described [16]. Results shown
are mean þ S.D. of three separate experiments.
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treated lymphoblasts (Fig. 1). However, a signi¢cant increase
in GMD activity (about four-fold) was also observed in con-
trol EBV-transformed cells over that of the IL-2 stimulated
lymphoblasts. EBV-transformed lymphocytes from both par-
ents of the patient featured GMD activity levels intermediate
between those of the patient himself and the control cells. The
corresponding time-dependent pro¢les of activity were closer
to the linear patterns observed in the control immortalized
cells than to the upward concave behavior of the patient cells,
especially at the lower concentrations of substrate (not
shown).
Fig. 2B illustrates the substrate saturation curves of GMD
activity in lysates of immortalized lymphocytes from the LAD
II patient, from his parents and from a representative control
subject. While a clear de¢ciency of GMD activity was ob-
served in the LAD II patient cells as compared to the control
transformed lymphocytes, the cells from both father and
mother displayed intermediate activity levels. Apparently, no
di¡erences were observed in the Km values of GMD from the
four di¡erent samples, which were around 5 WM GDP-D-man-
nose in all cases. However, another distinctive property of the
patient GMD was a remarkable inhibition by high substrate
concentrations, which could never be observed in control cells,
while its extent was comparatively and equally lower in EBV-
transformed lymphocytes from both father and mother (Fig.
2B). FX levels of enzymatic activity were comparable in all
examined samples (84 þ 5.6 nmol/h/mg cytosolic protein), thus
excluding any parallel involvement also of this enzyme in
LAD II.
GMDs from both patient and control were then investi-
gated by Western blot analyses of the corresponding cytosolic
fractions, using a rabbit polyclonal antibody raised against
recombinant E. coli GMD, which, due to the presence of a
high sequence homology [17], is able to cross-react also with
the human protein. As shown in Fig. 3, a band corresponding
to GMD was also present in the patient cells, in amounts
comparable to those found in the control. An additional im-
munoreactive band of approximately 20 kDa was also ob-
served in patient lymphocytes, but it is still unclear whether
this represents a shorter form of the protein or a possible
product of degradation.
Sequence of the coding region of the GMD cDNA obtained
from the patient cells consistently revealed that no amino acid
substitution is present in the patient, compared to the pub-
lished sequence obtained from HL-60 cell line [17] and to the
sequence concurrently and independently achieved in our lab-
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Fig. 4. SDS-PAGE analysis [25] of recombinant GMD from patient
(lanes 1, 2 and 3) and control (lanes 4, 5 and 6) lymphocytes, ex-
pressed as fusion proteins with GST. Lanes 1 and 4, puri¢ed GMD
recovered after Prescission protease cleavage; lanes 2 and 5, e¥uent
from GST-Sepharose; lanes 3 and 6, bacterial cytosolic fraction re-
covered after cell lysis and centrifugation at 14 000Ug. The gel was
stained with Coomassie brilliant blue. After cleavage GMD mi-
grated with an apparent Mr of approximately 43 kDa compared to
known standards, consistent with the expected size derived from the
amino acid sequence.
Fig. 3. Western blot analysis on the cytosolic fraction of patient
(lane 1) and control (lane 2) lymphoblasts using a polyclonal anti-
GMD antibody. 50 Wg of total protein was loaded onto each lane
and subjected to SDS-PAGE under reducing conditions on a 12%
acrylamide gel [25] and to blotting on nitrocellulose membrane. De-
tection was achieved by the ECL method.
Fig. 2. A: Activity of GMD in the cytosolic fraction of EBV-trans-
formed lymphocytes during incubation at 37‡C with 50 WM GDP-D-
[14C-U]mannose, using 1 mg/ml of protein. Data from a representa-
tive experiment are shown. B: Speci¢c activities of GMD in the cy-
tosolic fraction of EBV-transformed lymphocytes from control, the
LAD II patient and his parents as function of GDP-D-mannose
concentrations. Results are mean þ S.D. of four separate experi-
ments.
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oratory upon cloning GMD from normal human lympho-
cytes.
Another unequivocal indication that the defect in GMD
activity observed in cell lysates from patient cells is not due
to a qualitatively modi¢ed protein came from the expression
and comparative assay of speci¢c enzymatic activities of the
normal enzyme and the patient GMD, both derived form
lymphocytes as recombinant proteins (see Section 2.4). These
were obtained in a pure form (Fig. 4, lanes 1 and 4) and
displayed a comparable GMD activity of 42 þ 3 Wmol/h/mg
of protein. The Km values were 3.0 þ 0.5 WM GDP-D-mannose
for both patient and control recombinant GMDs. Addition of
cofactors, such as NAD or NADP, had no e¡ect whatso-
ever on the activity of both enzymes. Recombinant human FX
was added at the end of incubation with both control and
patient GMDs and led to the complete disappearance of the
intermediate compound formed, thus indicating that the prod-
uct of two enzyme proteins is indeed GDP-4-keto-6-deoxy-D-
mannose.
4. Discussion
GMD from cells of the LAD II patient under study showed
rather unconventional kinetic properties as compared with the
enzyme from control cells. Deviation of enzymatic activity
from linearity during incubation would suggest some mecha-
nisms of time-dependent activation which remain so far un-
identi¢ed and which do not hold at all for the wild type
GMD. Likewise, the peculiarity of GMD inhibition by high
substrate concentrations, which was observed in the patient
cells only, seems to indicate a similarly altered catalytic mech-
anism. Both kinetic anomalies of GMD, i.e. apparent self-
activation and inhibition by high substrate, were maintained,
although to a comparatively lower extent, in the cells of the
two heterozygous LAD II subjects that were investigated in
parallel. GMD protein, as determined by Western blot experi-
ments, was apparently present in patient cells in amounts not
lower than in the control cells, thus ruling out the hypothesis
of a defective activity due to reduced intracellular levels of the
enzyme protein.
Even though the data obtained strongly suggest the impair-
ment of GMD activity in the molecular pathogenesis of LAD
II syndrome, sequence analysis of cDNA and kinetic param-
eters of the recombinant GMD in the patient seem to exclude
the presence of a mutation either a¡ecting the catalytic activ-
ity of the enzyme or responsible for a lower enzyme stability.
Mutations in the non-coding regions of the gene, potentially
a¡ecting mRNA expression, stability or translation, can be
similarly excluded by the ¢nding of comparable amounts of
GMD protein in the cytosolic fraction from both control and
patient cells. Moreover, the unusual kinetic properties shown
by GMD in the cytosolic fraction of patient cells cannot be
obviously explained by reduced levels of the protein.
The only likely explanation for an enzyme de¢ciency asso-
ciated with normal intracellular levels of a structurally normal
enzyme protein seems to be a genetic mutation in an as yet
unknown protein involved in the control of GMD activity,
which can be altered following cell disruption and the subse-
quent enzymatic assay in vitro, thus explaining the apparent
self-activation consistently observed during incubation.
Further studies are required to identify possible regulatory
mechanisms of GMD, both in normal and pathological con-
ditions, such as LAD II syndrome or other diseases in which
an alteration in L-fucose metabolism seems to be involved, e.g.
advanced neoplastic or in£ammatory diseases [28^30]. Of par-
ticular interest is the observation that after immortalization of
B-lymphocytes with EBV, all cell lines are characterized by a
signi¢cant increase in GMD activity, compared to that ob-
served after PHA+IL-2 stimulation. It is still unclear whether
these quantitative di¡erences could be due to the presence of
di¡erent lymphocyte populations or, alternatively, be an e¡ect
related to cell immortalization. Since GDP-L-fucose is the
substrate of fucosyltransferases, elucidation of regulatory
mechanisms of the metabolic pathway leading to its produc-
tion, and especially of its rate-limiting reaction, could give
further insights also into the complex regulation of biosyn-
thesis and remodeling of fucosylated glycoconjugates.
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